FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): December 12, 2025
Neuphoria Therapeutics Inc.
(Exact name of Registrant as Specified in its Charter)
Delaware
(State Or Other Jurisdiction of Incorporation)
| 001-41157 | 99-3845449 | |
| (Commission File Number) | (I.R.S. Employer Identification No.) |
| 100 Summit Dr, Burlington, Massachusetts | 01803 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(781) 439-5551
Registrant’s Telephone Number, Including Area Code
Securities registered pursuant to Section 12(b) of the Act
| Title of Each Class | Trading Symbol | Name of each exchange on which registered | ||
| Common Stock, $0.00001 par value per share | NEUP | The Nasdaq Stock Market, LLC |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On December 12, 2025, the Company held an Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on the four proposals described below. The proposals presented at the Annual Meeting are described in detail in the Definitive Proxy Statement filed with the Securities and Exchange Commission on November 24, 2025.
Of the 2,357,613 shares of Common Stock outstanding and entitled to vote at the Annual Meeting, 937,447, or 39.76%, of the outstanding and eligible shares, were present either in person or by proxy and entitled to vote on all proposals. Holders of Common Stock voted one vote per share on all matters properly brought before the Annual Meeting.
The results for each of the proposals submitted to a vote of shareholders at the Annual Meeting are as follows:
Proposal No. 1 – Election of two class I directors for a three-year term
With respect to the proposal for the election of two Class I directors for a three year term, the voting with respect to Proposal 1 was as follows:
| Nominee | For | Withheld | ||||||
| Peter Miles Davies | 759,850 | 152,879 | ||||||
| David Wilson | 758,571 | 154,164 | ||||||
| Stephen Doberstein | 136,780 | 775,959 | ||||||
| Kimberly Smith | 136,740 | 775,997 | ||||||
Proposal No. 2 – Ratify the appointment of our auditor for the fiscal year ended June 30, 2026
With respect to the proposal to ratify the appointment of Wolf & Company P.C. as our independent registered public accounting firm for the fiscal year ending June 30, 2026, the voting with respect to Proposal 2 was as follows:
| For | Against | Abstain | ||
| 807,022 | 96,245 | 34,180 |
1
Proposal No. 3 – Approve (on a non-binding advisory basis) the compensation of our named executive officers
With respect to the proposal to approve (on a non-binding advisory basis) the compensation of our named executive officers, the voting with respect to Proposal 3 was as follows:
| For | Against | Abstain | ||
| 726,184 | 154,109 | 32,445 |
Proposal No. 4 – Approve (on a non-binding advisory basis) the frequency of holding an advisory vote on the compensation of our named executive officers
With respect to the proposal to approve (on a non-binding advisory basis) the frequency of holding an advisory vote on the compensation of our named executive officers in future years, the voting with respect to Proposal 4 was as follows:
| 1 year | 2 years | 3 years | Abstain | |||
| 184,974 | 27,153 | 585,857 | 109,526 |
2
SIGNATUREs
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NEUPHORIA THERAPEUTICS INC. | ||
| By: | /s/ Spyridon Papapetropoulos | |
| Spyridon Papapetropoulos | ||
| Chief Executive Officer | ||
| Date: December 17, 2025 | ||
3